
Forget antimicrobials, Evelo just raised $50M for its pro-microbial approach
Evelo Biosciences is doing pretty well for a preclinical company in an exploratory field. The 2014 startup has already executed a merger and raised $100 million in venture financing for its so-called "monoclonal microbials."